Tumor-infiltrating lymphocytes and colorectal cancer survival in Africa Namerican and Caucasian Patients

Cancer Epidemiology Biomarkers and Prevention

Volumn 27, Issue 7, 2018, Pages 755-761

  Wallace, Kristin ^a,b   Lewin, David N ^a,b   Sun, Shaoli ^a,b   Spiceland, Clayton M ^b   Rockey, Don C ^b   Alekseyenko, Alexander V ^a,b   Wu, Jennifer D ^c   Baron, John A ^d   Alberg, Anthony J ^a,b   Hill, Elizabeth G ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INFILTRATION; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE RESPONSE; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE DIFFERENCE; TUMOR ASSOCIATED LEUKOCYTE;

EID: 85049620190     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-17-0870     Document Type: Article

References (55)

1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RGS, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017;67: 177-193.
2. Andaya AA, Enewold L, Zahm SH, Shriver CD, Stojadinovic A, McGlynn KA, et al. Race and colon cancer survival in an equal-access health care system. Cancer Epidemiol Biomarkers Prev 2013;22:1030-6.
3. Wallace K, DeToma A, Lewin DN, Sun S, Rockey D, Britten CD, et al. Racial differences in stage IV colorectal cancer survival in younger and older patients. Clin Colorectal Cancer. 2017;16:178-86
4. Holowatyj AN, Ruterbusch JJ, Rozek LS, Cote ML, Stoffel EM. Racial/ethnic disparities in survival among patients with young-onset colorectal cancer. J Clin Oncol 2016;34:2148-56.
5. Yoon HH, Shi Q, Alberts SR, Goldberg RM, Thibodeau SN, Sargent DJ, et al. Racial differences in BRAF/KRAS mutation rates and survival in stage III colon cancer patients. J Natl Cancer Inst 2015;107. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758035/pdf/djv186.pdf.
6. Du XL, Meyer TE, Franzini L. Meta-analysis ofracial disparities insurvival in association with socioeconomic status among men and women with colon cancer. Cancer 2007;109:2161-70.
7. Robbins AS, Siegel RL, Jemal A. Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol 2012;30:401-5.
8. Yan B, Noone AM, Yee C, Banerjee M, Schwartz K, Simon MS. Racial differences in colorectal cancer survival in the detroit metropolitan area. Cancer 2009;115:3791-800.
9. Byers TE, Wolf HJ, Bauer KR, Bolick-Aldrich S, Chen VW, Finch JL, et al. The impact of socioeconomic status on survival after cancer in the United States: findings from the national program of cancer registries patterns of care study. Cancer 2008;113:582-91.
10. Breslin TM, Morris AM, Gu N, Wong SL, Finlayson EV, Banerjee M, et al. Hospital factors and racial disparities in mortality after surgery for breast and colon cancer. J Clin Oncol 2009;27:3945-50.
11. Boissiere-Michot F, Lazennec G, Frugier H, Jarlier M, Roca L, Duffour J, et al. Characterization of an adaptive immune response in microsatellite-instable colorectal cancer. Oncoimmunology 2014;3:e29256.
12. Berntsson J, Nodin B, Eberhard J, Micke P, Jirström K. Prognostic impact of tumour-infiltratingB cells and plasma cells in colorectal cancer. Int JCancer 2016;139:1129-39.
13. Prizment AE, Vierkant RA, Smyrk TC, Tillmans LS, Nelson HH, Lynch CF, et al. Cytotoxic T cells and granzyme B associated with improved colorectal cancer survival in a prospective cohort of older women. Cancer Epidemiol Biomarkers Prev 2017;26:622-631.
14. Mbow M, de Jong SE, Meurs L, Mboup S, Dieye TN, Polman K, et al. Changes in immunological profile as a function of urbanization and lifestyle. Immunology 2014;143:569-77.
15. Roetynck S, Olotu A, Simam J, Marsh K, Stockinger B, Urban B, et al. Phenotypic and functional profiling of CD4 T cell compartment in distinct populations of healthy adults with different antigenic exposure. PLoS One 2013;8:e55195.
16. Ye CJ, Feng T, Kwon HK, Raj T, Wilson MT, Asinovski N, et al. Intersection of population variation and autoimmunity genetics in human T cell activation. Science 2014;345:1254665.
17. Labuda LA, de Jong SE, Meurs L, Amoah AS, Mbow M, Ateba-Ngoa U, et al. Differences in innate cytokine responses between European and African children. PLoS One 2014;9:e95241.
18. Russell SB, Smith JC, Huang M, Trupin JS, Williams SM. Pleiotropic effects of immune responses explain variation in the prevalence of fibroproliferative diseases. PLoS Genet 2015;11:e1005568.
19. Halvorsen TB, Seim E. Association between invasiveness, inflammatory reaction, desmoplasia and survival in colorectal cancer. J Clin Pathol 1989;42:162-6.
20. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006;313: 1960-4.
21. Jass JR. Lymphocytic infiltration and survival in rectal cancer. J Clin Pathol 1986;39:585-9.
22. Menon AG, Janssen-van Rhijn CM, Morreau H, Putter H, Tollenaar RA, van de Velde CJ, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 2004;84:493-501.
23. Galon J, Pages F, Marincola FM, Thurin M, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med 2012;10:1.
24. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013;39:782-95.
25. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009;137: 1270-9.
26. Maby P, Tougeron D, Hamieh M, Mlecnik B, Kora H, Bindea G, et al. Correlation between density of CD8+ T-cell infiltrate in micro satellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res 2015;75:3446-55.
27. Tosolini M, Kirilovsky A, Mlecnik B, Fredriksen T, Mauger S, Bindea G, et al. Clinical impact of differ ent classes ofinfiltratingTcytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011;71:1263-71.
28. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009;15:6412-20.
29. Basa RC, Davies V, Li X, Murali B, Shah J, Yang B, et al. Decreased anti-tumor cytotoxic immunity among microsatellite-stable colon cancers from African Americans. PLoS One 2016;11:e0156660.
30. Carethers JM, Murali B, Yang B, Doctolero RT, Tajima A, Basa R, et al. Influence of race on microsatellite instability and CD8+ T cell infiltration in colon cancer. PLoS One 2014;9:e100461.
31. Wallace K, Hill EG, Lewin DN, Williamson G, Oppenheimer S, Ford ME, et al. Racial disparities in advanced-stage colorectal cancer survival. Cancer Causes Control 2013;24:463-71.
32. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, et al. CpG island methylator phenotype, micro satellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-6.
33. McCoy AN, Araujo-Perez F, Azcarate-Peril A, Yeh JJ, Sandler RS, Keku TO. Fusobacterium is associated with colorectal adenomas. PLoS One 2013;8: e53653.
34. Park NJ, Kang DH. Inflammatory cytokine levels and breast cancer risk factors: racial differences of healthy Caucasian and African American women. Oncol Nurs Forum 2013;40:490-500.
35. Jovov B, Araujo-Perez F, Sigel CS, Stratford JK, McCoy AN, Yeh JJ, et al. Differential gene expression between African American and European American colorectal cancer patients. PLoS One 2012;7:e30168.
36. Corley DA, Jensen CD, Marks AR, Zhao WK, de Boer J, Levin TR, et al. Variation of adenoma prevalence by age, sex, race, and colon location in a large population: implications for screening and quality programs. Clin Gastroenterol Hepatol 2013;11:172-80.
37. Lieberman DA, Williams JL, Holub JL, Morris CD, Logan JR, Eisen GM, et al. Race, ethnicity, and sex affect risk for polyps >9 mm in average-risk individuals. Gastroenterology 2014;147:351-8.
38. Friedenberg FK, Singh M, George NS, Sankineni A, Shah S. Prevalence and distribution of adenomas in black Americans undergoing colorectal cancer screening. Dig Dis Sci 2012;57:489-95.
39. Xicola RM, Gagnon M, Clark JR, Carroll T, Gao W, Fernandez C, et al. Excess of proximal microsatellite-stable colorectal cancer in African Americans from a multiethnic study. Clin Cancer Res 2014;20:4962-70.
40. Diaz-Montero CM, Finke J, Montero AJ. Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications. Semin Oncol 2014;41:174-84.
41. Akazawa Y, Kubo M, Zhang R, Matsumoto K, Yan F, Setiawan H, et al. Inhibition of arginase ameliorates experimental ulcerative colitis in mice. Free Radic Res 2013;47:137-45.
42. OuYang LY, Wu XJ, Ye SB, Zhang RX, Li ZL, Liao W, et al. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. J Transl Med 2015;13:47.
43. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci 2014;1319:47-65.
44. Ortiz ML, Kumar V, Martner A, Mony S, Donthireddy L, Condamine T, et al. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells. J Exp Med 2015;212:351-67.
45. Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 2013;8:e57114.
46. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J 2010;16:348-53.
47. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350-6.
48. Wang L, Ren F, Wang Q, Baldridge LA, Monn MF, Fisher KW, et al. Significance of programmed death ligand 1 (PD-L1) immunohisto-chemical expression in colorectal cancer. Mol Diagn Ther 2016;20: 175-81.
49. Boland PM, Ma WW. Immunotherapy for colorectal cancer. Cancers 2017;9. https://www.ncbi.nlm.nih.gov/pubmed/28492495.
50. Pauken KE, Wherry EJ. Overcoming T cell exhaustion in infection and cancer. Trends Immunol 2015;36:265-76.
51. Zarour HM. Reversing T-cell dysfunction and exhaustion in cancer. Clin Cancer Res 2016;22:1856-64.
52. Nedelec Y, Sanz J, Baharian G, Szpiech ZA, Pacis A, Dumaine A, et al. Genetic ancestry and natural selection drive population differences in immune responses to pathogens. Cell 2016; 167: 657-69.
53. Sanoff HK, Sargent DJ, Green EM, McLeod HL, Goldberg RM. Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol 2009;27:4109-15.
54. Polite BN, Sing A, Sargent DJ, Grothey A, Berlin J, Kozloff M, et al. Exploring racial differences in outcome and treatment for metastatic colorectal cancer: results from a large prospective observational cohort study (BRiTE). Cancer 2012;118:1083-90.
55. Elamin YY, Rafee S, Toomey S, Hennessy BT. Immune effects of bevacizumab: killing two birds with one stone. Cancer Microenviron 2015;8:15-21.